124
Participants
Start Date
December 2, 2025
Primary Completion Date
February 11, 2027
Study Completion Date
February 11, 2027
AZD4144
Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned.
Placebo
Intravenous solution of Placebo will be administered to randomised participants according to the treatment arm to which they have been assigned.
Research Site, Budapest
Research Site, Brussels
Research Site, Brussels
Research Site, Ottignies
Research Site, CABA
Research Site, Rosario
Research Site, Hvidovre
Research Site, Tatabánya
Research Site, Genk
Research Site, Debrecen
Research Site, Szeged
Research Site, Kaposvár
Research Site, Pécs
Research Site, Aarhus N
Research Site, Aalborg
Research Site, The Bronx
Research Site, Jerez de la Frontera
Research Site, Athens
Research Site, Greifswald
Research Site, Prague
Research Site, Philadelphia
Research Site, Rozzano
Research Site, Milan
Research Site, Baltimore
Research Site, Kiel
Research Site, Winston-Salem
Research Site, Charleston
Research Site, Padua
Research Site, Tours
Research Site, Kocaeli
Research Site, Valencia
Research Site, Kahramanmaraş
Research Site, Detroit
Research Site, Angers
Research Site, Aachen
Research Site, Adapazarı
Research Site, Thessaloniki
Research Site, Frankfurt
Research Site, Heidelberg
Research Site, Salt Lake City
Research Site, Tucson
Research Site, La Roche-sur-Yon
Research Site, Limoges
Research Site, Newport Beach
Research Site, Corvallis
Research Site, Boston
Research Site, Ciudad de Buenos Aires
Research Site, La Plata
Research Site, Montreal
Research Site, Montreal
Research Site, Québec
Research Site, Prague
Research Site, Strasbourg
Research Site, Leipzig
Research Site, Roma
Research Site, Barcelona
Research Site, Ankara
Research Site, Brighton
Research Site, Guildford
Research Site, Liverpool
Research Site, London
Lead Sponsor
AstraZeneca
INDUSTRY